Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisSTE +2.04%91 3-Year EBITDA Growth Rate is 6.40% as of Jun. 2026, which is 37% below its 10-year median of 10.10. GuruFocus rates STE with a GF Score™ of 91/100 and a GF Value™ of $269.10 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Steris ranks worse than 53.04% on this metric.
During the past 12 months, Steris's average EBITDA Per Share Growth Rate was 17.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Steris was 522.00% per year. The lowest was -26.00% per year. And the median was 10.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Steris 3-Year EBITDA Growth Rate Related Terms
STE vs ZBH, GEHC, DXCM: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Steris's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Steris's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.40% mean?
Steris (STE) has a 3-Year EBITDA Growth Rate of 6.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Steris and its competitors. This is 37% below median its historical median of 10.10. According to the industry distribution chart, Steris ranks #366 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 53%.
Is Steris' 3-Year EBITDA Growth Rate too high?
Steris' current 3-Year EBITDA Growth Rate of 6.40% is 37% below median its 10-year median of 10.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.35. Steris' value of 6.40% is 23.4% below this industry median. Based on the distribution chart, Steris ranks #366 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Steris has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' 3-Year EBITDA Growth Rate compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #366 out of 690 companies for 3-Year EBITDA Growth Rate. This places Steris in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.35. Steris' value of 6.40% is 23.4% below this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 8.35, Steris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.35, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current 3-Year EBITDA Growth Rate of 6.40% is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Steris and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current 3-Year EBITDA Growth Rate is 6.40%, which is 37% below median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (STE) is currently considered Modestly Undervalued. The stock's GF Value™ is $269.10, compared to a current price of $237.14 — trading 11.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.40%, which is 37% below median its 10-year median of 10.10 and 23.4% below the Medical Devices & Instruments industry median of 8.35. Steris' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Steris (STE), the current 3-Year EBITDA Growth Rate is 6.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (STE) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of $237.14 is trading 11.9% below its estimated GF Value™ of $269.10.
GuruFocus considers Steris to be Modestly Undervalued.
Key valuation signals for STE:
3-Year EBITDA Growth Rate: 6.40% (37% below median its 10-year median of 10.10)
GF Value™: $269.10 vs. price of $237.14 (11.9% below fair value)
Industry Position: 23.4% below the Medical Devices & Instruments median (#366 of 690)
No single metric tells the full story. See the STE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
91GF Score
Get the complete analysis for STE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STE has been successfully added to your 
